Collaborations & Alliances

Agenus, Gilead Milestone Triggers $7.5M Payment

FDA acceptance of IND filing for AGEN237 represents the second milestone in Gilead partnership achieved in 2019

Agenus Inc. announced that the FDA has accepted the company’s IND filing for AGEN2373, a milestone in its partnership with Gilead Sciences, Inc. This milestone triggers a cash payment of $7.5 million. Agenus is eligible to receive additional milestone payments this year and beyond.   “This IND clearance underscores our continued commitment to delivering novel and best-in-class therapies to patients with cancer with the utmost urgency,” said Garo H. Armen, Ph.D., Chairman and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters